logo

TEVA

Teva Pharmaceutical·NYSE
--
--(--)
--
--(--)
6.07 / 10
Outperform

Analyst coverage is overwhelmingly positive (Strong Buy 66.7%, Buy 33.3%) with high historical win rates, indicating strong conviction. Fund-flow data show robust overall and block inflows (positive trends) but smaller outflows in the Medium and Small categories. The fund-flow score of 7.74/10 is good, aligning with the bullish analyst view. Together, the analyst and funding sides reinforce a cautiously optimistic tone, though not enough to override the fundamental and technical concerns.

FundamentalSentiment(6.07)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

67%

Buy

33%

Hold

0%

Sell

0%

Strong Sell

0%

Date2026-01-30
InstitutionBarclays
Times predicted3
Historical Win Rate100.0%
What is the analyst consensus for TEVA?
  • TEVA holds a Bearish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.07/10 (Outperform).